CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Copper Cu 64 TP3805 +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02989623
NCT02989623N/ACompleted

A Pilot Phase I Open Label Study of Cu-64-TP3805 PET Imaging for Detection of Prostate Cancer in Men With Persistently Elevated PSA

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·interventional·Posted Dec 12, 2016·Updated Apr 24, 2025

In Brief

A clinical study evaluating Copper Cu 64 TP3805 and Positron Emission Tomography and Computed Tomography Scan for Prostate Cancer. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This pilot phase I trial studies how well copper Cu 64 TP3805 positron emission tomography (PET) works in detecting prostate cancer in patients with persistently elevated prostate specific antigen (PSA). The copper Cu 64 TP3805 PET scan uses copper Cu 64 TP3805, a compound made of a radioactive agent attached to a molecule that looks like a hormone that binds to cancer cells to detect prostate cancer during PET scans. Copper Cu 64 TP3805 PET may be able to see tumors at an earlier stage than the standard of care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 12, 2016
Enrollment StartSep 1, 2015
Primary CompletionApr 24, 2019
Study CompletionApr 25, 2019
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.6 years ago

Interventions

Copper Cu 64 TP3805radiation

Given Intravenously

Positron Emission Tomography and Computed Tomography Scanprocedure

Undergo copper Cu 64 TP3805 PET/CT scan